CA-XRAN-FOUNDATION
27.2.2017 08:03:01 CET | Business Wire | Press release
The xRAN Foundation, a consortium dedicated to promoting a software-based, extensible Radio Access Network (xRAN) and to standardizing critical elements of the xRAN architecture, today announced that Verizon, a global leader of innovative mobile communications, technology and infrastructure and Ranzure, a provider of flexible, virtualized, cloud-based 4G/5G RAN solutions, have joined the xRAN Foundation. In addition to these key new members, the xRAN Foundation has announced a collaboration with M-CORD , the open source project reinventing network access to bring datacenter economics and cloud agility to service providers’ central offices.
“A network architecture that provides a robust, interactive abstraction layer between applications and RAN infrastructure fits very well with our vision and goals. We believe this approach creates opportunities to increase the efficiency of our network and improve the quality of experience for our subscribers,” said Adam Koeppe, Vice President, Network Technology Planning at Verizon. “The xRAN Foundation has demonstrated the feasibility of a decoupled approach. The combination of standardized north-bound and south-bound interfaces allows the development of applications that can intelligently interact with the RAN infrastructure in a way that has never been possible before. We are excited to join the xRAN Foundation and plan to actively evaluate solutions that support xRAN interfaces and architecture.”
“For an efficient delivery of next generation mobile services, such as AR, IoT and industrial robotics, a new more flexible software-based and hardware independent RAN architecture is required. The xRAN approach will offer us real time programmability and control of our RAN infrastructure to dynamically adapt to our customers' needs,” said Bruno Jacobfeuerborn, CTO, Deutsche Telekom. “We are excited to see xRAN and CORD Project join forces to drive the development of this approach.”
Formally formed in October of 2016 by AT&T, Deutsche Telekom, SK Telecom, Intel Corporation, Texas Instruments, Radisys, Aricent and Stanford University, the xRAN Foundation is a consortium dedicated to promoting a software-based, extensible Radio Access Network (xRAN) and to standardizing critical elements of the xRAN architecture. The xRAN architecture transforms today’s static, highly-proprietary RAN infrastructure into an extensible, software-based service delivery platform capable of rapidly responding to changing user, application and business needs.
The xRAN Foundation is holding a panel discussion event at Mobile World Congress 2017 in Barcelona on Tuesday February 28th at noon on the Deutsche Telekom main presentation stage in Hall 3. The event will include an introduction presentation by Deutche Telekom CTO, Bruno Jacobfeuerborn, followed by a panel discussion moderated by Petr Ledl, Head of Deutsche Telekom 5G:haus. The panel includes Dr. Sachi Katti, Stanford University, Dr. Kim Larsen, Technology Economics & Transformation (TET) & AI Technology Architecture & Innovation (TAI) Group Technology at Deutsche Telekom, Gordon Mansfield, Vice President RAN & Device Design at AT&T, and Caroline Chan, VP and GM, 5G Infrastructure Division, Network Platform Group, at Intel.
A multi-vendor demonstration of the xRAN controller, featuring the Intel + Radisys and the Texas Instruments + Aricent reference platforms, will be hosted during Mobile World Congress. Register for a demo here: http://xran.org/mwc
About xRAN Foundation
The xRAN Foundation was formed to develop, standardize and promote an open alternative to the traditionally closed, hardware-based RAN architecture. xRAN fundamentally advances RAN architecture in three areas – decouples the RAN control plane from the user plane, builds a modular eNB software stack that operates on common-off-the-shelf (COTS) hardware and publishes open north- and south-bound interfaces to the industry. For more information about xRAN Foundation membership go to xran.org/membership or email info@xran.org . For more information on xRAN architecture, download the xRAN Architecture white paper . To schedule a briefing with xRAN member representatives at Mobile World Congress in Barcelona, please contact pr@xran.org .
View source version on businesswire.com: http://www.businesswire.com/news/home/20170226005155/en/
Contact:
xRAN Foundation
Rod Stuhlmuller
rod@xran.org
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Announces US FDA Approval for Label Extensions of ALYFTREK® and TRIKAFTA®, Expanding Availability of These Medicines to ~95% of All People With CF in the United States1.4.2026 13:30:00 CEST | Press release
-With this expansion, any variant that results in production of CFTR protein is now included in the indication for ALYFTREK and TRIKAFTA, reinforcing the impact these medicines have, regardless of the location of the variant in the CFTR protein--Approximately 800 more people with CF in the US are now eligible for a CFTR modulator for the first time- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved expanded use of ALYFTREK® (vanzacaftor/tezacaftor/ivacaftor) for the treatment of people with cystic fibrosis (CF) ages 6 and older with a variant in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is either responsive based on clinical and/or in vitro data or results in production of CFTR protein. Additionally, the U.S. FDA has also expanded the indication statement for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in patients ages 2 and older. This label expansion was supported b
Agenus Announces First Patient Enrolled in Global Phase 3 BATTMAN Trial of BOT+BAL Immunotherapy Combination in MSS or pMMR Metastatic Colorectal Cancer1.4.2026 13:30:00 CEST | Press release
A Landmark Registrational Study Aiming to Redefine Outcomes in MSS mCRC Which Represents Approximately 95% of Metastatic Colorectal Cancer CasesColorectal Cancer Has Become the Leading Cause of Cancer-related Death in Adults Under Age 50 Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that the first patient has been enrolled in the landmark global phase 3 BATTMAN (CO.33) trial (NCT07152821). This study is evaluating Agenus’ immunotherapy combination of botensilimab (BOT) plus balstilimab (BAL) versus best supportive care in patients with refractory, unresectable microsatellite stable (MSS)/mismatch repair proficient (pMMR) metastatic colorectal cancer (mCRC), a population long considered resistant to immunotherapy. This study is being conducted as a cooperative group trial led by the Canadian Cancer Trials Group (CCTG) from Canada and run across Canada, France, Australia and New Zealand. More than 100 sites will participate across the academic cooper
Klarna Agrees to $1.7 Billion Transaction Supporting up to $40B+ of Lending1.4.2026 13:19:00 CEST | Press release
Klarna, the global digital bank and flexible payments provider, has entered into a new capital efficiency transaction in the form of a Significant Risk Transfer (SRT), covering $1.7 billion-worth of Euro denominated loans and freeing up capital to support continued growth. Klarna has entered into a three-year agreement with a consortium led by Värde Partners. This is Klarna's sixth SRT transaction and improves how effectively Klarna deploys its capital on a global basis. "Our banking license is one of our biggest competitive advantages," said Niclas Neglén, Klarna's Chief Financial Officer. "This is our largest and most efficient SRT transaction to date. These transactions allow us to maximize every unit of capital to support our continued momentum." The transaction follows Klarna’s recently announced $2 billion facility supporting $17B of US Financing expansion. About Klarna Klarna is a global digital bank and flexible payments provider. With over 118 million global active Klarna user
Americhem Launches nDryve™: PFAS-Free In-Melt Technology Platform for Functional Fibers1.4.2026 13:00:00 CEST | Press release
Americhem, Inc., a global polymer solutions provider, today announced the launch of nDryve™, a PFAS-free, in-melt surface-modifying technology platform designed to deliver durable multi-fluid repellency against alcohol and other low-surface-energy fluids in fiber systems. As global regulations accelerate the phase-out of per- and polyfluoroalkyl substances (PFAS), manufacturers are under increasing pressure to maintain barrier performance without fluorinated chemistries. nDryve™ was developed to address this shift, offering a PFAS-free, in-melt alternative to conventional surface applied treatments. Engineered for Performance Without PFAS Often referred to as “forever chemicals,” PFAS have come under heightened regulatory scrutiny due to their persistence and potential environmental and health impacts. nDryve™ integrates directly into the polymer during melt processing, embedding surface-modifying functionality within the fiber matrix rather than relying on removable finishes. By engin
Biocytogen and Sihuan Pharmaceutical Announce Strategic Partnership in Weight Loss and Beyond1.4.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced a strategic partnership with Sihuan Pharmaceutical Holdings Group Ltd. (Sihuan Pharmaceutical; HKEX: 00460). Under the agreement, both parties will combine Biocytogen’s leading fully human antibody discovery platform with Sihuan Pharmaceutical’s extensive capabilities in drug development, manufacturing, and commercialization. The collaboration will focus on advancing innovative therapies across multiple disease areas, including weight loss, leveraging complementary strengths to drive synergies and establish a long-term strategic partnership. Sihuan Pharmaceutical highly values the strength of Biocytogen’s technology platforms. In this collaboration, Biocytogen will leverage its integrated platforms, including proprietary target-humanized mouse models and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom